Performance
Revenue ($m)
$2,553mOperating profit ($m)
$582mCore¹ operating profit ($m)
$632mEBITDA² ($m)
$727mProfit to shareholders ($m)
$421mBasic earnings per share³ (cents)
182cCore basic earnings per share³ (cents)
195cDividend per share (cents)
54c- Core results are presented to show the underlying performance of the Group, excluding the exceptional items and other adjustments set out in Note 6 of the Group consolidated financial statements
- EBITDA is earnings before interest, tax, depreciation, amortisation, asset write-down and impairment charges
- In June 2020, Hikma purchased 12.8 million ordinary shares from Boehringer Ingelheim,
which are being held in treasury
Interim results 2022
Watch full video - Interim results 2022
Key financial highlights from Said Darwazah, Chairman and CEO
Key financial highlights from Khalid Nabilsi, Chief Financial Officer
Key financial highlights from Riad Mishlawi, President, Injectables
Key financial highlights from Mazen Darwazah, Executive Vice Chairman and President, MENA video
Key financial highlights from Brian Hoffmann, President Generics
Four reasons to invest in Hikma
We have a strong business model with significant opportunities to further enhance our portfolio to drive growth and deliver value for shareholders.
Understanding Hikma
Find out how our business model, strategy and established capabilities support our clear investment proposition
Results and presentations
Regulatory news
News feed from the London Stock Exchange's Regulatory News Service.
Download our Corporate Factsheet
Information on the high standards of governance we’re committed to, our governance structure, Board, key committees, and remuneration policy.